DC Field | Value | Language |
---|---|---|
dc.contributor.author | Son, Sumin | ko |
dc.contributor.author | Park, Jinho | ko |
dc.contributor.author | Seo, Hyo Deok | ko |
dc.contributor.author | Lee, Hyun Tae | ko |
dc.contributor.author | Heo, Yong-Seok | ko |
dc.contributor.author | Kim, Hak-Sung | ko |
dc.date.accessioned | 2020-05-15T02:20:05Z | - |
dc.date.available | 2020-05-15T02:20:05Z | - |
dc.date.created | 2019-10-14 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.citation | JOURNAL OF DRUG TARGETING, v.28, no.4, pp.419 - 427 | - |
dc.identifier.issn | 1061-186X | - |
dc.identifier.uri | http://hdl.handle.net/10203/274204 | - |
dc.description.abstract | Immune checkpoint inhibitors have drawn a consider attention as an effective cancer immunotherapy, and several monoclonal antibodies targeting the immune checkpoint receptors, such as human programmed cell death-1 (hPD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are clinically used for treatment of various cancers. Here we present the development of a small-sized protein binder which specifically binds to hPD-1. The protein binder, which is composed of leucine-rich repeat (LRR) modules, was selected against hPD-1 through phage display, and its binding affinity was maturated up to 17 nM by modular evolution approach. The protein binder was shown to be highly specific for hPD-1, effectively inhibiting the interaction between hPD-1 and its ligand, hPD-L1. The protein binder restored T-cell function in vitro, and exhibited a strong anti-tumour activity in tumour mouse model, indicating that it acts as an effective checkpoint blockade. Based on the results, the developed protein binder specific for hPD-1 is likely to find a potential use in cancer immunotherapy. | - |
dc.language | English | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model | - |
dc.type | Article | - |
dc.identifier.wosid | 000487864200001 | - |
dc.identifier.scopusid | 2-s2.0-85073918290 | - |
dc.type.rims | ART | - |
dc.citation.volume | 28 | - |
dc.citation.issue | 4 | - |
dc.citation.beginningpage | 419 | - |
dc.citation.endingpage | 427 | - |
dc.citation.publicationname | JOURNAL OF DRUG TARGETING | - |
dc.identifier.doi | 10.1080/1061186X.2019.1669042 | - |
dc.contributor.localauthor | Kim, Hak-Sung | - |
dc.contributor.nonIdAuthor | Park, Jinho | - |
dc.contributor.nonIdAuthor | Lee, Hyun Tae | - |
dc.contributor.nonIdAuthor | Heo, Yong-Seok | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | PD-1 | - |
dc.subject.keywordAuthor | immune checkpoint inhibitor | - |
dc.subject.keywordAuthor | non-antibody scaffold | - |
dc.subject.keywordAuthor | repebody | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODIES | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | CHECKPOINT BLOCKADE | - |
dc.subject.keywordPlus | DEATH 1 | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | CHALLENGES | - |
dc.subject.keywordPlus | ANTI-PD-1 | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.